“Altamira emerged from the 2023 business year as a stronger and more focused company,” commented Thomas Meyer, Altamira Therapeutics’ founder, Chairman, and CEO. “We keep progressing with our RNA delivery business, concluding recently our second collaboration agreement with another exciting biotech company. With the recent partial spin-off of our Bentrio legacy business we took a significant first step on our journey towards becoming a fully focused RNA delivery company. We expect to complete the strategic repositioning of the Company through partnering the remaining legacy assets in 2024. At the same time, we managed to streamline our cost structure and strengthen our balance sheet by eliminating all financial debt and rebuilding shareholders’ equity. We look forward to moving to our next milestones in 2024.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTO:
- Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024
- Biotech Alert: Searches spiking for these stocks today
- Altamira Therapeutics enters collaboration with Univercells
- Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines
